New NICE guideline [NG99] Brain tumours (primary) and brain metastases in adults
Published date:
This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.
For full guidance
https://www.nice.org.uk/guidance/ng99
Showing posts with label xMH. Show all posts
Showing posts with label xMH. Show all posts
Wednesday, 11 July 2018
New NICE guideline [NG98] Hearing loss in adults: assessment and management
New NICE guideline [NG98] Hearing loss in adults: assessment and management
Published date:
This guideline covers some aspects of assessing and managing hearing loss in primary, community and secondary care. It aims to improve the quality of life for adults with hearing loss by advising healthcare staff on assessing hearing difficulties, managing earwax and referring people for audiological or specialist assessment and management.
For full guidance
https://www.nice.org.uk/guidance/ng98
Published date:
This guideline covers some aspects of assessing and managing hearing loss in primary, community and secondary care. It aims to improve the quality of life for adults with hearing loss by advising healthcare staff on assessing hearing difficulties, managing earwax and referring people for audiological or specialist assessment and management.
For full guidance
https://www.nice.org.uk/guidance/ng98
Wednesday, 13 June 2018
New NIHR Signal Balance of long-term benefits and risks of caesarean delivery explained
New NIHR Signal Balance of long-term benefits and risks of caesarean delivery explained
Published on 12 June 2018
Caesarean delivery has immediate known benefits and risks for those women who need help in childbirth. This review measures the long-term outcomes for the mothers’ health, the links to a higher risk of childhood illness and the chance of problems with future pregnancies.
From the NIHR Dissemination Centre
https://discover.dc.nihr.ac.uk/content/signal-000601/balance-of-long-term-benefits-and-risks-of-caesarean-delivery-explained
New NIHR Signal Fewer side-effects and similar benefits from shorter chemotherapy after bowel cancer surgery
New NIHR Signal Fewer side-effects and similar benefits from shorter chemotherapy after bowel cancer surgery
Published on 12 June 2018
A three-month course of chemotherapy after surgery for bowel cancer seems no less effective than the standard six-month course, and half as many people suffered from nerve damage as a side-effect. Three-quarters of people survived to three years without disease progression on either treatment.
From the NIHR Dissemination Centre
https://discover.dc.nihr.ac.uk/content/signal-000603/fewer-side-effects-and-similar-benefits-from-shorter-chemotherapy-after-bowel-cancer-surgery
New NIHR Signal Aspirin may be a follow-on option to prevent blood clots, starting five days after hip or knee surgery
New NIHR Signal Aspirin may be a follow-on option to prevent blood clots, starting five days after hip or knee surgery
Published on 5 June 2018
In a recent trial, switching to low-dose aspirin was just as effective at preventing blood clots after joint replacement surgery as continuing the anti-clotting drug rivaroxaban. Six per 1,000 people taking aspirin experienced a blood clot, compared with seven per 1,000 taking rivaroxaban. Three to five per 1,000 patients experienced major bleeding with either drug.
From the NIHR Dissemination Centrre
https://discover.dc.nihr.ac.uk/content/signal-000599/aspirin-may-be-a-follow-on-option-to-prevent-blood-clots-starting-five-days-after-surgery
New NIHR Signal Prescribing anti-inflammatories for urine infection reduces antibiotic use but increases complication risk
New NIHR Signal Prescribing anti-inflammatories for urine infection reduces antibiotic use but increases complication risk
Published on 5 June 2018
Urinary tract infection symptoms resolved by three days for 80% of women given antibiotics compared with 54% given anti-inflammatories. Anti-inflammatories reduced antibiotic use, but 5% of women developed more severe infection of the kidneys.
From the NIHR Dissemination centre
https://discover.dc.nihr.ac.uk/content/signal-000598/anti-inflammatories-for-urine-infection-reduces-antibiotic-use-but-increases-complication-risk
New NIHR Signal Plastic wraps or bags keep pre-term infants warm immediately after birth
New NIHR Signal Plastic wraps or bags keep pre-term infants warm immediately after birth
Published on 22 May 2018
Cheap and simple plastic wrapping used in the first 10 minutes after birth helps pre-term and low birth weight infants avoid hypothermia. Infants treated in this way are likely to be warmer when admitted to neonatal intensive care than those treated according to standard care. Pre-term infants are most likely to benefit.
From the NIHR Dissemination Centre
https://discover.dc.nihr.ac.uk/content/signal-00596/plastic-wraps-or-bags-keep-pre-term-infants-warm-immediately-after-birth
New NIHR Signal Cell salvage during caesarean section doesn’t reduce blood transfusions
New NIHR Signal Cell salvage during caesarean section doesn’t reduce blood transfusions
Published on 15 May 2018
In a large UK trial, cell salvage for women at risk of blood loss during caesarean did not reduce the need for donor blood transfusion, though few needed transfusion (2.5% compared with 3.5% among controls).
From the NIHR Dissemination Centre
https://discover.dc.nihr.ac.uk/content/signal-00592/cell-salvage-during-c-section-doesnt-reduce-blood-transfusions
Published on 15 May 2018
In a large UK trial, cell salvage for women at risk of blood loss during caesarean did not reduce the need for donor blood transfusion, though few needed transfusion (2.5% compared with 3.5% among controls).
From the NIHR Dissemination Centre
https://discover.dc.nihr.ac.uk/content/signal-00592/cell-salvage-during-c-section-doesnt-reduce-blood-transfusions
New NIHR Signal Probiotics can prevent bacterial diarrhoea in hospital patients receiving antibiotics
New NIHR Signal Probiotics can prevent bacterial diarrhoea in hospital patients receiving antibiotics
Published on 1 May 2018
Giving probiotics to people taking antibiotics reduces the chance of them developing diarrhoea caused by Clostridium difficile (C. difficile) bacteria by 60%. One case of Clostridium-associated diarrhoea was prevented for every 42 people receiving probiotics. They appear to work best for patients at more than 5% risk of Clostridium infection.
From the NIHR Dissemination Centre
https://discover.dc.nihr.ac.uk/content/signal-00589/probiotics-to-prevent-diarrhoea-caused-by-c-difficile
New NIHR Signal Atraumatic needles reduce headaches following lumbar puncture
New NIHR Signal Atraumatic needles reduce headaches following lumbar puncture
Published on 17 April 2018
Use of atraumatic needles rather than conventional needles for lumbar puncture more than halves the rate of post-procedure headache. Moreover, this improvement does not come at the expense of procedure success rates.
From the NIHR Dissemination Centre
https://discover.dc.nihr.ac.uk/content/signal-00583/atraumatic-needles-reduce-headaches-following-lumbar-puncture
New Technology appraisal guidance [TA526] Arsenic trioxide for treating acute promyelocytic leukaemia
New Technology appraisal guidance [TA526] Arsenic trioxide for treating acute promyelocytic leukaemia
Published date:
Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.
For full guidance https://www.nice.org.uk/guidance/ta526
New Technology appraisal guidance [TA524] Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
New Technology appraisal guidance [TA524] Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Published date:
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.
For full guidance https://www.nice.org.uk/guidance/ta524
New Technology appraisal guidance [TA523] Midostaurin for untreated acute myeloid leukaemia
New Technology appraisal guidance [TA523] Midostaurin for untreated acute myeloid leukaemia
Published date: Next review: June 2021
Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.
For full guidance https://www.nice.org.uk/guidance/ta523
New Technology appraisal guidance [TA522] Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
New Technology appraisal guidance [TA522] Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Published date: Next review: More evidence on pembrolizumab is being collected, until November 2019. After this, NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then, as part of the managed access agreement
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial carcinoma in adults.
for full guidance https://www.nice.org.uk/guidance/ta522
New Technology appraisal guidance [TA521] Guselkumab for treating moderate to severe plaque psoriasis
New Technology appraisal guidance [TA521] Guselkumab for treating moderate to severe plaque psoriasis
Published date: Next review: June 2021
For full guidance https://www.nice.org.uk/guidance/ta521
New Technology appraisal guidance [TA520] Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
New Technology appraisal guidance [TA520] Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Published date:
Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.
For full guidance https://www.nice.org.uk/guidance/ta520
Subscribe to:
Posts (Atom)